Social services; coverage for fertility diagnostic care, treatment, and preservation services; provide
HB589 would require Georgia’s Department of Community Health to amend the state Medicaid plan to cover fertility diagnostic care, fertility treatment, and fertility preservation services beginning January 1, 2026. The bill defines key terms such as infertility, fertility patient, fertility preservation services, fertility treatment, and experimental fertility procedure, and ties covered services to established medical practice and professional guidelines from the American Society for Reproductive Medicine or a comparable organization.
The bill specifies that coverage must include at least three complete egg retrievals with unlimited embryo transfers from those retrievals, subject to medical appropriateness and single-embryo transfer recommendations when applicable. It also requires coverage for fertility preservation for individuals facing medical conditions or treatments that may impair fertility, and it bars discrimination in coverage based on race, color, religion, national origin, sex, sexual orientation, gender, mental disability, or physical disability. The Department of Community Health would also be directed to report to the General Assembly by August 1, 2026 on possible ways to cover in-vitro fertilization and standard fertility preservation services as Medicaid benefits, including waiver options and funding needs.
HB589 would amend Georgia’s Medicaid laws in Title 49 to add fertility-related benefits for eligible fertility patients and to require the Department of Community Health to pursue any necessary state plan amendment or federal waiver. It would expand covered services to include fertility diagnostics, fertility treatment, fertility preservation, ovulation-enhancing drugs, related medical services, and intrauterine insemination, while excluding experimental procedures and nonmedical costs tied to donor gametes, donor embryos, or surrogacy. The bill would also create a reporting obligation for the department regarding broader IVF coverage and potential financing.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the measure appears to be framed as a health coverage expansion with a strong access-to-care rationale. The bill’s structure suggests support for fertility treatment access, fertility preservation, and nondiscrimination in coverage, while also attempting to limit costs by excluding experimental and nonmedical services. No formal vote history or transcript evidence is available here to show organized opposition or support, but the bill’s subject matter indicates a generally pro-coverage posture.
The main points of potential contention are likely to be cost, scope, and federal Medicaid compliance. The requirement for at least three egg retrievals and unlimited embryo transfers, along with coverage for ovulation-enhancing drugs, intrauterine insemination, and fertility preservation, could raise concerns about program expense and administrative complexity. Another likely issue is whether IVF and related fertility services can be covered under Medicaid without a federal waiver or other federal approval, which the bill acknowledges by directing the department to consult CMS and seek waivers if needed. Questions may also arise over the bill’s definitions, exclusions for experimental procedures, and the treatment of donor gametes, embryos, and surrogacy-related costs.